NEW METHOD FOR DETECTING CANCER AND VIRAL INFECTD CELLS

第一阶段研究的目标是开发一种快速、自动化的方法来 分析分离的细胞核或细胞中的DNA或RNA异常 微胶囊技术、荧光原位杂交 和流式细胞术。这种新的微滴原位杂交方法 (MISH)有望改善疾病的早期发现并做出贡献 基因组和细胞遗传学研究。 由于个体、染色体、细胞和细胞核不能抵抗 在溶液中的杂交条件，使用流式细胞术 染色体分析目前还不可行。与…形成对比 显微镜和最近的数字图像分析，这很高 吞吐量分析技术的独特之处在于它能够快速 分析大量的生物实体，并对小的 亚种群。FISH技术在流式细胞术中的应用 将极大地增加可以进行的化验的数量 用于研究和临床细胞遗传学。 基因异常与多种疾病状态有关， 包括肿瘤的发生、转移和白血病。检测罕见的 表达病毒特异性RNA或不表达宿主的细胞- 编码的基因，如肿瘤抑制基因，也可能戏剧性地 使用这项独特的技术进行了改进。一项额外的申请 包括对细胞表达的定性或定量分析 用于研究和临床应用的特定信使核糖核酸水平。 细胞遗传学检测仍处于初级阶段。新基因的发现和 它们的功能是制药公司密集努力的重点 公司和基因组研究人员。这些治疗努力也是 有望支持新的基因检测方法的快速发展 测试。 建议的商业应用： 分子细胞遗传学检测还处于初级阶段。发展迅速， 高通量检测人类免疫缺陷基因异常的方法 较低的数字将改善诊断和治疗药物的开发。这个 鱼类检测市场预计将增长到每年10亿美元 到2010年。

Phase I research is aimed at developing a rapid, automated method to analyze DNA or RNA aberrations in isolated nuclei or cells using microencapsulation technology, fluorescence in situ hybridization (FISH) and flow cytometry. This novel microdrop in situ hybridization method (MISH) is expected to improve early disease detection and to contribute to genomic and cytogenetic research. Since individual, chromosomes, cells and nuclei do not withstand hybridization conditions in solution, use of flow cytometry for chromosome analysis is not currently feasible. In contrast with microscopy and more recently digital image analysis, this high throughput analytical technique is distinctive in its ability to rapidly analyze large numbers of biological entities and to quantitate small sub-populations. Adaptation of FISH procedures for flow cytometric use would dramatically expand the number of assays which could be performed for research and clinical cytogenetics. Genetic aberrations are implicated in a variety of disease states, including tumorigenesis, metastasis, and leukemias. Detection of rare cells, which are expressing virus specific RNAs or not expressing host- coded genes, such as tumor suppressor genes, could also be dramatically improved using this unique technology. An additional application includes qualitative or quantitative analyses of cells expressing specific mRNA levels for both research and clinical applications. Cytogenetic testing is still in its infancy. Discovery of new genes and their functions are the focus of intensive efforts by pharmaceutical companies and genome researchers. These therapeutic efforts are also expected to support rapid development of new assay methods for genetic testing. PROPOSED COMMERCIAL APPLICATION: Molecular cytogenetic testing is in its infancy. Development of rapid, high throughput assay methods for detecting gene aberrations present in low numbers will improve diagnosis and therapeutic drug development. The market for FISH assays is expected to increase to $1.0 billion annually by 2010.